Rallybio Stock Faces a $50 Million Test as Traders Weigh What Comes Next
Rallybio Corp shares were little changed before the Nasdaq open on Friday, with the latest available market-data print at $14.52, up about 0.3% from the previous close, as investors kept the stock near levels reached after a $50 million deal-termination payment earlier this month. That matters now because there has been no fresh company press-release catalyst in the last 24 to 48 hours, leaving price action to test whether the May re-rating can hold. Rallybio’s investor-relations feed lists its latest news releases as the March 2 Candid merger announcement, a Feb. 17 RLYB116 data release and a Feb. 3 reverse-stock-split notice.